ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Abstracts tagged "Disease Activity and clinical trials"

  • Abstract Number: 2513 • ACR/ARP Annual Meeting 2019

    Relationships Between Psoriatic Arthritis Disease Activity Score and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies

    Laura Coates1, Andrew Bushmakin 2, Oliver FitzGerald 3, Dafna Gladman 4, Lara Fallon 5, Joseph Cappelleri 2, Ming-Ann Hsu 6 and Philip Helliwell 7, 1University of Oxford, Oxford, United Kingdom, 2Pfizer Inc, Groton, CT, 3University College Dublin, Dublin, Ireland, 4University of Toronto, Toronto, ON, Canada, 5Pfizer Inc, Montreal, QC, Canada, 6Pfizer Inc, Collegeville, PA, 7University of Leeds, Leeds, United Kingdom

    Background/Purpose: Psoriatic arthritis (PsA) is a complex heterogeneous disease associated with multiple domains. Psoriatic Arthritis Disease Activity Score (PASDAS) is a composite disease activity measure…
  • Abstract Number: 2514 • ACR/ARP Annual Meeting 2019

    Relationships Between Minimal Disease Activity and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies

    Philip Helliwell1, Andrew Bushmakin 2, Dafna Gladman 3, Oliver FitzGerald 4, Lara Fallon 5, Joseph Cappelleri 2, Ming-Ann Hsu 6 and Laura Coates 7, 1University of Leeds, Leeds, United Kingdom, 2Pfizer Inc, Groton, CT, 3University of Toronto, Toronto, ON, Canada, 4University College Dublin, Dublin, Ireland, 5Pfizer Inc, Montreal, QC, Canada, 6Pfizer Inc, Collegeville, PA, 7University of Oxford, Oxford, United Kingdom

    Background/Purpose: PsA is associated with multiple disease domains, requiring the use of different clinical measures and patient-reported outcomes (PROs) to assess improvements in disease activity…
  • Abstract Number: 2548 • ACR/ARP Annual Meeting 2019

    Abatacept Failed to Demonstrate Efficacy in an SLE Trial with Low Placebo Response Rates, Although Global Assessments Indicated Less Flare Severity

    Aikaterini Thanou1, Cristina Arriens 2, Teresa Aberle 1, Heather Miller 1, Lydia Mitchell 3, Stan Kamp 1, Anca Askanase 4, Stavros Stavrakis 5, Judith James 2 and Joan T. Merrill 6, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 3Oklahoma Medical Research Foundation, Oklahoma City, 4Columbia University, New York, 5University of Oklahoma Health Sciences Center, Oklahoma City, 6Okalahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: Abatacept (ABA) is a fusion protein of the extracellular domain of CTLA4 and human IgG1-Fc, constructed to inhibit B/T cell co-stimulation. Previous studies of…

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology